BCM-95® (CURCUGREEN®), 07 Aug 2021
Matthew B. Pickich, Mark W. Hargrove, C. Niles Phillips, James C. Healy, Angelique N. Moore, Michael D. Roberts and Jefrey S. Martin
Objective: We recently reported that curcumin supplementation in a metabolically (i.e., Western diet [WD]) and chemically (i.e., CCl4) induced female rat model of non-alcoholic steatohepatitis (NASH) was associated with lower liver pathology scores and molecular markers of infammation. This occurred when curcumin was given during induction of disease (preventative arm; 8-week WD with or without curcumin [8WD+C vs. 8WD]) as well as when given after disease development (treatment arm; 12-week WD with or without curcumin during weeks 9–12 [12WD+C vs. 12WD]). Herein, we sought to extend our fndings from that study by determining the efects of curcumin supplementation on cytokine/chemokine expression in serum collected from these same rats.
Results: 24 cytokines/chemokines were assayed. IL-2 (+80%) and IL-13 (+83%) were greater with curcumin supplementation in the prevention arm. IL-2 (+192%), IL-13 (+87%), IL-17A (+81%) and fractalkine (+121%) were higher while RANTES was lower (−22%) with curcumin supplementation in the treatment arm (p<0.05 for all). RANTES concentrations also correlated signifcantly with hepatic pathology scores of infammation (r=0.417, p=0.008). Select serum cytokines/chemokines were afected with curcumin supplementation in this female rat model of NASH.
Moreover, curcumin’s efect(s) on RANTES and its association with liver disease pathogenesis and progression may warrant further investigation.